Core Mechanism and Indications of Tepotinib

Core Mechanism and Indications of Tepotinib

Tepotinib is a precision targeted therapy that works by specifically inhibiting the MET protein, which drives cancer growth. By blocking the MET signaling pathway, this drug helps control the progression of metastatic non-small cell lung cancer (mNSCLC), allowing patients to focus on what truly matters in life. Tepotinib is the only once-daily oral therapy approved for adult patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (METex14) as confirmed by a test. METex14 skipping mutation is a specific genetic alteration that causes continuous cancer cell proliferation and spread. Before using tepotinib, physicians must confirm the presence of this biomarker in the patient's tumor tissue through a validated test to ensure targeted treatment. The recommended dose is 450 mg once daily, taken with food. It is not known whether tepotinib is safe and effective in children; therefore, it is indicated only for adult patients. If you or your loved one has been diagnosed with metastatic non-small cell lung cancer, we encourage you to proactively discuss the need for METex14 testing with your doctor to determine whether tepotinib is an appropriate treatment option.

Know Your MET Status – The Importance of METex14 Testing

Knowing the MET status of your tumor is the critical first step to determine if you may benefit from tepotinib therapy. METex14 is a specific biomarker indicating the presence of MET exon 14 skipping mutation, a genetic abnormality that continuously drives the growth and metastasis of non-small cell lung cancer. If you or your loved one has been diagnosed with metastatic non-small cell lung cancer and has not yet been tested for METex14, be sure to ask your doctor about arranging this test. Testing is typically performed by genetic analysis of tumor tissue samples or liquid biopsy, and the results can clarify whether the tumor carries this specific mutation. A positive test result means you have METex14 mutation-positive mNSCLC and may be a candidate for good response to MET inhibitors such as tepotinib. Conversely, if the result is negative, tepotinib should not be used. Your physician will develop an individualized treatment plan based on your test results. Notably, about 3% to 4% of all patients with non-small cell lung cancer (approximately 5,700 to 8,100 people annually in the United States) carry METex14 mutations. Therefore, knowing your MET status is not only a prerequisite for precision treatment but also an important safeguard against ineffective or harmful therapy.

Important Safety Warning for Tepotinib

Tepotinib may cause serious and life-threatening swelling of the lungs (i.e., lung inflammation or pneumonitis) during treatment, which can be fatal. Therefore, all patients receiving tepotinib must be highly vigilant for any new or worsening lung-related symptoms. These symptoms include: difficulty breathing, shortness of breath, unexplained cough, and fever. If any of these manifestations occur, patients should contact their healthcare provider immediately without delay. The physician will assess the severity of symptoms and decide whether to interrupt treatment, adjust the dose, or permanently discontinue tepotinib. It is important to emphasize that lung inflammation is not an ordinary cold or bronchitis; it can progress very rapidly, and early recognition and intervention are crucial. To minimize risk, patients should undergo regular clinical assessments of lung function during treatment and proactively report any unusual changes in breathing to their doctor. If you have any pre-existing lung or respiratory diseases (e.g., chronic obstructive pulmonary disease, interstitial pneumonia, etc.), you must inform your doctor before starting treatment, as these underlying conditions may increase the risk of severe lung inflammation.